Drug–Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Drug–Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism ; day:27 ; month:11 ; year:2023 ; pages:1-18
Drugs in R & D ; (27.11.2023), 1-18
- Urheber
-
Ferri, Nicola
Martin, Sara De
Stuart, James
Traversa, Sergio
Folli, Franco
Pappagallo, Marco
O’Gorman, Cedric
Guidetti, Clotilde
Mattarei, Andrea
Inturrisi, Charles E.
Manfredi, Paolo L.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40268-023-00450-6
- URN
-
urn:nbn:de:101:1-2024021413375681459223
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:37 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ferri, Nicola
- Martin, Sara De
- Stuart, James
- Traversa, Sergio
- Folli, Franco
- Pappagallo, Marco
- O’Gorman, Cedric
- Guidetti, Clotilde
- Mattarei, Andrea
- Inturrisi, Charles E.
- Manfredi, Paolo L.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Overactive Bladder Prescribing Considerations: The Role of Polypharmacy, Anticholinergic Burden, and CYP2D6 Drug‒Drug Interactions
Characteristics of CYP3A4-related potential drug-drug interactions in outpatients receiving prescriptions from multiple clinical departments
Investigating the complexity of time-dependent drug-drug and drug-food interactions involving CYP3A4 using physiologically based pharmacokinetic modeling
Prediction of drug–drug interactions between roflumilast and CYP3A4/1A2 perpetrators using a physiologically-based pharmacokinetic (PBPK) approach
Physiologically based pharmacokinetic modeling of CYP3A4, CYP1A2 and transporter substrates, inhibitors and inducers for the prediction of drug-drug interactions
A Review of Daclatasvir Drug–Drug Interactions
Drug–Drug Interactions with Direct Oral Anticoagulants
Extracting drug-drug interactions from biomedical texts
Lurasidone drug-drug interaction studies: a comprehensive review
Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions
Pharmacovigilance of Drug–Drug Interactions with Nirmatrelvir/Ritonavir
Case report: Medical cannabis—warfarin drug-drug interaction
Overactive Bladder Prescribing Considerations: The Role of Polypharmacy, Anticholinergic Burden, and CYP2D6 Drug‒Drug Interactions
Characteristics of CYP3A4-related potential drug-drug interactions in outpatients receiving prescriptions from multiple clinical departments
Investigating the complexity of time-dependent drug-drug and drug-food interactions involving CYP3A4 using physiologically based pharmacokinetic modeling
Prediction of drug–drug interactions between roflumilast and CYP3A4/1A2 perpetrators using a physiologically-based pharmacokinetic (PBPK) approach
Physiologically based pharmacokinetic modeling of CYP3A4, CYP1A2 and transporter substrates, inhibitors and inducers for the prediction of drug-drug interactions
A Review of Daclatasvir Drug–Drug Interactions
Drug–Drug Interactions with Direct Oral Anticoagulants
Extracting drug-drug interactions from biomedical texts
Lurasidone drug-drug interaction studies: a comprehensive review
Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions
Pharmacovigilance of Drug–Drug Interactions with Nirmatrelvir/Ritonavir
Case report: Medical cannabis—warfarin drug-drug interaction
Overactive Bladder Prescribing Considerations: The Role of Polypharmacy, Anticholinergic Burden, and CYP2D6 Drug‒Drug Interactions
Characteristics of CYP3A4-related potential drug-drug interactions in outpatients receiving prescriptions from multiple clinical departments
Investigating the complexity of time-dependent drug-drug and drug-food interactions involving CYP3A4 using physiologically based pharmacokinetic modeling
Prediction of drug–drug interactions between roflumilast and CYP3A4/1A2 perpetrators using a physiologically-based pharmacokinetic (PBPK) approach
Physiologically based pharmacokinetic modeling of CYP3A4, CYP1A2 and transporter substrates, inhibitors and inducers for the prediction of drug-drug interactions
A Review of Daclatasvir Drug–Drug Interactions
Drug–Drug Interactions with Direct Oral Anticoagulants
Extracting drug-drug interactions from biomedical texts
Lurasidone drug-drug interaction studies: a comprehensive review
Delta-9-Tetrahydrocannabinol and Cannabidiol Drug-Drug Interactions
Pharmacovigilance of Drug–Drug Interactions with Nirmatrelvir/Ritonavir